Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.52M
Average 0.39M
SION Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Sionna Therapeutics, Inc.NASDAQ: SION
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables declines year over year
Q1 FY2026 accounts payables of $1.21M fell 66.0% year over year, ahead of the -217.5% change in trailing-twelve-month accounts payables. Over 3 fiscal years it compounded at -34.9% a year.
Context
- Accounts payables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -66.0% holds above the trailing-twelve-month pace of -217.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- (417K) USD
- Year-over-year change
- -189.3%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (417K) | -189.3% |
| FY2024 | 2024-12-31 | 467K | +188.3% |
| FY2023 | 2023-12-31 | 162K | +110.7% |
| FY2022 | 2022-12-31 | (1.51M) | — |
Accounts Payables vs competitors
How SION compares with its peers on the latest reported figures
- SION's LTM Mar 2026 accounts payables of $2.76M is the 6th largest of the 11 companies compared; the peer median is $1.06M.
- Its year-over-year change of -217.5% is the 10th highest of 11, against a peer median of +129.8%.
- Over three fiscal years its annual growth of -34.9% compares with a peer median of +9.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $45.36M | +357.1% | — | 17.1% | |
| LTM Mar 2026 | $14.47M | +507.1% | -21.1% | 3.4% | |
| LTM Sep 2026 | $13.63M | -5.5% | +52.3% | 12167.9% | |
| LTM Sep 2026 | $7.53M | +229.2% | +48.0% | 11.1% | |
| LTM Jun 2026 | $7.51M | -417.2% | — | — | |
| LTM Mar 2026 | $2.76M | -217.5% | -34.9% | — | |
| LTM Mar 2026 | $1.61M | +159.9% | -80.7% | 8.0% | |
| LTM Sep 2026 | $1.13M | -147.6% | +138.3% | — | |
| LTM Jun 2026 | $1.12M | -86.9% | +9.5% | — | |
| LTM Mar 2026 | $1M | +148.6% | — | 4.6% | |
| LTM Mar 2026 | $119K | +111.0% | -74.8% | 0.0% | |
| Peer median (excluding SION) | $1.06M | +129.8% | +9.5% | 8.0% | |
Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Sionna Therapeutics, Inc.
NASDAQ:SION
Intrinsic Alpha fair value
Locked
Current Price
$2.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.